Sarah Cannon Research Institute | Strategic Alliance Partners

April 17, 2020

Erika P. Hamilton, MD, director of the Breast Cancer and Gynecologic Research Program and principal investigator at Sarah Cannon Research Institute, discusses the FDA approval of tucatinib (Tukysa) in HER2-positive breast cancer.

April 11, 2020

Stephanie L. Graff, MD, discusses genomic risk prediction in patients with hormone receptor–positive, HER2-negative breast cancer.

April 09, 2020

Erika P. Hamilton, MD, director of the Breast Cancer and Gynecologic Research Program and principal investigator at Sarah Cannon Research Institute, discusses the use of pathologic complete response (pCR) as a way to classify risk status in HER2-positive breast cancer.

March 31, 2020

Jesus Berdeja, MD, the director of Multiple Myeloma Research at Sarah Cannon Research Institute, discusses updated data with bb21217 in multiple myeloma.

March 30, 2020

Carlos R. Bachier, MD, discusses the use of CAR T-cell therapy in the outpatient setting. He also shared insight on the evolving paradigm of graft-versus-host disease.

February 14, 2020

Erika P. Hamilton, MD, discusses the superiority of ado-trastuzumab emtansine (T-DM1; Kadcyla) in the phase III KATHERINE study.

February 06, 2020

Erika P. Hamilton, MD, director of the Breast Cancer and Gynecologic Research Program and principal investigator at Sarah Cannon Research Institute, discusses the phase II DESTINY-Breast01 trial in advanced HER2-positive breast cancer.

February 05, 2020

Howard A. "Skip" Burris, III, MD, FASCO, FACP, chief medical officer and president, Clinical Operations, Sarah Cannon Research Institute, 2019-2020 ASCO president-elect, and a 2014 Giant of Cancer Care® in Drug Development, discusses investigational immunotherapy approaches in triple-negative breast cancer (TNBC).

January 18, 2020

Howard A. "Skip" Burris, III, MD, FASCO, FACP, chief medical officer and president, Clinical Operations, Sarah Cannon Research Institute, 2019 ASCO president-elect, and a 2014 Giant of Cancer Care® in Drug Development, discusses ongoing research with antibody-drug conjugates (ADCs) in triple-negative breast cancer.

January 16, 2020

Howard A. "Skip" Burris, III, MD, FACP, FASCO, discusses the progress that has been made in metastatic triple-negative breast cancer and the work being done to broaden the utility of novel approaches.

January 16, 2020

Denise Yardley, MD, discusses the utility of CDK4/6 inhibitors in hormone receptor

January 15, 2020

Stephanie L. Graff, MD, discusses the importance of using genomic risk to tailor treatment to patients with early-stage hormone receptor-positive, HER2-negative disease, the benefit of extended endocrine therapy, and ongoing research with CDK4/6 inhibitors and immunotherapy.

January 15, 2020

Stephanie L. Graff, MD, discusses the utility of extended adjuvant therapy in women with early-stage hormone receptor-positive, HER2-negative breast cancer.

January 14, 2020

Erika P. Hamilton, MD, discusses research presented at the 2019 San Antonio Breast Cancer Symposium and how the data are impacting the treatment of patients with HER2-positive breast cancer.

January 14, 2020

Denise Yardley, MD, discusses the implications of CDK4/6 inhibitors in hormone receptor-positive/HER2-negative breast cancer. 

January 10, 2020

Howard "Skip" A. Burris, III, MD, chief medical officer and president, Clinical Operations, Sarah Cannon Research Institute, 2019 ASCO president-elect, and a 2014 Giant of Cancer Care® in Drug Development, discusses the incorporation of biosimilars in oncology.

January 10, 2020

Erika P. Hamilton, MD, director, Breast Cancer and Gynecologic Research Program, Sarah Cannon Research Institute, discusses the phase II HER2CLIMB trial in metastatic HER2-positive breast cancer.

December 03, 2019

Erika P. Hamilton, MD, discusses the results of the phase III KATHERINE trial in HER2-positive breast cancer.

November 13, 2019

Erika P. Hamilton, MD, discussed several studies in the HER2-positive breast cancer space and the sequencing challenges that have emerged.

November 12, 2019

Erika P. Hamilton, MD, discusses the impact of biosimilars in oncology.